ImmunoPrecise Antibodies (IPA) announced that it has received formal notification from Nasdaq confirming that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 11, stated that for the 10 consecutive business days from June 26, through July 10, the closing bid price of the company’s common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPA:
- ImmunoPrecise Antibodies Strengthens Board with Industry Veteran Jon Lieber
- ImmunoPrecise’s LENSai Platform Achieves Breakthrough in Antibody Binding Prediction
- ImmunoPrecise Antibodies announces new validation study on LENSai
- ImmunoPrecise Advances Universal Dengue Vaccine with AI-Driven Discovery
- ImmunoPrecise Antibodies provides update on dengue vaccine breakthrough